Drug

Clarithromycin

In clinical development

ClassBacterial 70S ribosome inhibitorEmerging researchLate-stage development

Also known as Biaxin, CLA, Claritromicina, 6-O-methyl erythromycin+4 more

Biaxin, CLA, Claritromicina, 6-O-methyl erythromycin, 6-O-methylerythromycin, Clarithromycina, Clarithromycine, Clarithromycinum.

RxNorm21212 ChEMBLCHEMBL1741 ATCJ01FA09UNIIH1250JIK0A

Research papers

Active clinical trials

Protein targets

Latest activity

beta

Recent clinical, regulatory, research and industry developments relating to this drug.

A Multicenter, Open-label Clinical Study to Evaluate the Preliminary Efficacy of SKB264 and the Effect of Clarithromycin, a Potent CYP3A Inhibitor, on the Pharmacokinetics of SKB264 in Patients With Ovarian Epithelial Cancer

Clinical trial2026-06-01Results expected Q1 2028 · ClinicalTrials.gov

The Effect of Vitamin D Supplement as Adjuvant Therapy in Eradication of Helicobacter Pylori Infection

Clinical trial2026-06-01Primary completion · ClinicalTrials.gov

A Phase 1, Open-label, Drug Interaction Study to Investigate the Effect of Multiple Doses of Clarithromycin on the Pharmacokinetics of LY3502970 in Healthy Participants

Clinical trial2026-05-27Results posted · ClinicalTrials.gov

A Phase II Study of Daratumumab, Clarithromycin, Pomalidomide And Dexamethasone (D-ClaPd) In Multiple Myeloma Patients Previously Exposed to Daratumumab

Clinical trial2026-05-20Results posted · ClinicalTrials.gov

Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT)

Clinical trial2026-05-11Results expected Q2 2029 · ClinicalTrials.gov

A Phase 1b/2 Study of Selinexor (KPT-330) in Combination With Backbone Treatments for Relapsed/Refractory Multiple Myeloma and Newly Diagnosed Multiple Myeloma

Clinical trial2026-05-04Results expected Q2 2027 · ClinicalTrials.gov

A Phase 2/3, Multicenter, Randomized, Open-label, Active-controlled Study to Evaluate the Efficacy and Safety of Bedaquiline Administered as Part of a Treatment Regimen With Clarithromycin and Ethambutol in Adult Patients With Treatment-refractory Mycobacterium Avium Complex-lung Disease (MAC-LD)

Clinical trial2026-04-15Results posted · ClinicalTrials.gov

Biomarker-Guided Early Elarithromycin Treatment to Prevent Sepsis Progression in Community-Acquired Pneumonia: The React Randomized Clinical Trial

Clinical trial2026-04-05Primary completion · ClinicalTrials.gov

Comparison of Conventional Clarithromycin Vs Alternative Levofloxacin Based Regimen in Treatment of Helicobacter Pylori Infection

Clinical trial2026-03-01Primary completion · ClinicalTrials.gov

Safety and Efficacy of Vonoprazan vs Proton Pump Inhibitor With Vitamin D or Probiotics Based Triple Therapy for Eradication of Helicobacter Pylori Infection

Clinical trial2026-02-13Results expected Q4 2026 · ClinicalTrials.gov

Comparative Efficacy of Omeprazole and Vonoprazan in the Treatment of Helicobacter Pylori Infection

Clinical trial2026-02-01Primary completion · ClinicalTrials.gov

Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report.

Research2016-10-05Gut

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name

Clarithromycin

Aliases & brands

BiaxinCLAClaritromicina6-O-methyl erythromycin6-O-methylerythromycinClarithromycinaClarithromycineClarithromycinum

RxNorm CUI

21212

ChEMBL ID

CHEMBL1741

ATC codes

J01FA09

UNII

H1250JIK0A

Primary mechanism

Bacterial 70S ribosome inhibitor

Pharmacology & targets

55 targets

Known molecular targets and mechanisms supported by curated pharmacology databases.

Small ribosomal subunit protein uS2

rpsB · P0A7V0